Owkin and Proscia have announced a strategic partnership to streamline MSI testing for patients with colorectal cancer (CRC).
As a first step in the collaboration, the companies will integrate Owkin’s MSIntuit CRC v2 with Proscia’s Concentriq software platform for studying its impact and make it available as part of Proscia’s precision medicine AI portfolio to enable laboratories to keep pace with demand for MSI screening.
MSIntuit CRC v2, which will include analysis from biopsy samples, builds upon the success of the CE-IVD-certified MSIntuit CRC. Integrating MSIntuit CRC v2 into Concentriq as part of Proscia’s precision medicine AI portfolio could have the potential to expand access to the AI diagnostic in pathology labs. Concentriq is an enterprise pathology platform used by major laboratories for all aspects of their daily operations.
*In the US, MSIntuit CRC is under development and currently For Research Use Only. Not for use in diagnostic procedures. In Europe, MSIntuit CRC is under development and will be submitted for CE-IVDR marking.
